Skip to main content
H.R. 7539 118th Congress House

LOANS for Biomedical Research Act

Official title: To require the Secretary of the Treasury to guarantee BioBonds in order to provide funding for loans to eligible biomedical companies and universities to carry… Show full official titleShow less

Official title: To require the Secretary of the Treasury to guarantee BioBonds in order to provide funding for loans to eligible biomedical companies and universities to carry out clinical trials approved by the Food and Drug Administration, and for other purposes.

Introduced: March 5, 2024 Introduced by: Brian K. Fitzpatrick Republican · Pennsylvania See on congress.gov
Sign in to write a letter

Free account. One morning email at most, only on days something moved. Already have one? Sign in.

This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 8, 2024
Referred to the Subcommittee on Health.
Mar 5, 2024
Referred to the House Committee on Energy and Commerce.
Mar 5, 2024
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 8, 2024

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Long-term Opportunities for Advancing New Studies for Biomedical Research Act or the LOANS for Biomedical Research Act

This bill requires the Department of the Treasury to establish the BioBonds Program to support loans for clinical trials for eligible drugs and medical devices for unmet medical needs.

Under the program, fiscal agents purchase loans (up to $25 million per recipient) and issue collateralized bonds that are sold to investors and that are guaranteed by Treasury. An eligible borrower under this program is one conducting (or seeking to conduct) research related to a drug or device that is (1) intended to meet an unmet medical need; and (2) under investigation in certain types of controlled clinical trials, including a trial to investigate the safety and effectiveness of the drug or device. 

The Government Accountability Office (GAO) and Treasury must report on the program; GAO must also study whether similar programs should be established for other biomedical research projects.

 

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Lobbying activity 8

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 8 filings →
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 7539: LOANS for Biomedical Research Act. 118th Congress. Open America. https://openamerica.io/bill/118-HR-7539/
MLA
"H.R. 7539: LOANS for Biomedical Research Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-7539/.
Bluebook (legal)
H.R. 7539, 118th Cong. (2026), https://openamerica.io/bill/118-HR-7539/.
Markdown link
[H.R. 7539: LOANS for Biomedical Research Act](https://openamerica.io/bill/118-HR-7539/)
Report a problem